161 related articles for article (PubMed ID: 34903228)
21. The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment.
Li R; Ruckle HC; Schlaifer AE; El-Shafei A; Yu C; Jones JS
Urology; 2015 May; 85(5):1137-1142. PubMed ID: 25799176
[TBL] [Abstract][Full Text] [Related]
22. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
24. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis.
Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S
Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598
[TBL] [Abstract][Full Text] [Related]
25. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
26. Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients.
Kongnyuy M; Berg CJ; Kosinski KE; Habibian DJ; Schiff JT; Corcoran AT; Katz AE
Int J Hyperthermia; 2017 Nov; 33(7):810-813. PubMed ID: 28540788
[TBL] [Abstract][Full Text] [Related]
27. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A; Tangen C; Plets M; Morrison GJ; Cunha A; Xu T; Pinski JK; Ingles SA; Triche T; Harzstark AL; Kohli M; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Vogelzang NJ; Thompson IM; Agarwal N
Clin Cancer Res; 2021 Apr; 27(7):1967-1973. PubMed ID: 33500355
[TBL] [Abstract][Full Text] [Related]
28. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
29. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
31. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
32. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
[TBL] [Abstract][Full Text] [Related]
33. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
34. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
36. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer.
Keating MJ; Giscombe L; Tannous T; Reddy N; Mukkamalla SKR; DeSouza A; Rathore R
J Oncol Pharm Pract; 2019 Dec; 25(8):1927-1932. PubMed ID: 30880568
[TBL] [Abstract][Full Text] [Related]
37. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
38. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
Sargos P; Mottet N; Bellera C; Richaud P
BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients - Open-labeled randomized clinical trial.
Chen CH; Pu YS
Cryobiology; 2018 Jun; 82():88-92. PubMed ID: 29626465
[TBL] [Abstract][Full Text] [Related]
40. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
